Delving into the Latest Updates on Odetiglucan with Synapse

Overview

Basic Info

Drug Type

Polymer

Synonyms

Betafectin, Imprime, Imprime PGG

+ [4]

Target

CD11b x CD32A x CLEC7A

Action

activators, modulators, stimulants

Mechanism

CD11b activators(integrin subunit alpha M activators), CD32A activators(Low affinity immunoglobulin gamma Fc region receptor II-a activators), CLEC7A modulators(C-type lectin domain containing 7A modulators)

Therapeutic Areas

NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases

Active Indication

Colorectal Liver MetastasesMetastatic Colorectal CarcinomaBreast Cancer

Inactive Indication

Advanced Head and Neck Squamous Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaCarcinoma of ampulla of Vater+ [12]

Originator Organization

Biothera Pharmaceuticals, Inc. (Delaware)

Active Organization

Merck Sharp & Dohme LLC

HiberCell, Inc.

Inactive Organization-

License Organization

HiberCell, Inc.

AstraZeneca PLC

Biodesix, Inc.

+ [1]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

Start Date15 Dec 2022

Sponsor / Collaborator

HiberCell, Inc.

[+1]

NCT05159778

/ CompletedPhase 2

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

Start Date09 Nov 2021

Sponsor / Collaborator

HiberCell, Inc.

[+1]

100 Clinical Results associated with Odetiglucan

Login to view more data

100 Translational Medicine associated with Odetiglucan

Login to view more data

100 Patents (Medical) associated with Odetiglucan

Login to view more data

15

Literatures (Medical) associated with Odetiglucan

01 Jul 2025·JOURNAL OF IMMUNOLOGY

Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy

Article

Author: O’Shaughnessy, Joyce ; Drees, Jeremy ; Cox, Joanna ; Chmielowski, Bartosz ; Mattson, Paulette ; Osterwalder, Bruno ; Iglesias, Jose ; Gargano, Michele ; Mina, Lida ; Graff, Jeremy ; Abu-Khalaf, Maysa ; Dudek, Arkadiusz Z ; Stopeck, Alison T ; Rao, Ruta ; Harrison, Ben ; Uhlik, Mark ; Qiu, Xiaohong ; Chan, Anissa S H ; Xie, Bin ; Ottoson, Nadine ; Chisamore, Michael ; Bose, Nandita ; Borges, Virginia

Abstract:

The Phase 2 IMPRIME 1 study evaluated the combination of the pathogen-associated molecular pattern (PAMP) Imprime with the immune checkpoint inhibitor (ICI) pembrolizumab as second or later line of treatment (2 L+) for patients with metastatic triple-negative breast cancer (mTNBC). Eligible patients with mTNBC received weekly Imprime (4 mg/kg) intravenously in combination with pembrolizumab (200 mg every 3 weeks). Primary endpoints were overall response rate (ORR) and safety. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression free survival (PFS), and overall survival (OS). Exploratory endpoints included correlations between immune cell activation markers in tumor tissues and blood and response to therapy. Of the 42 evaluable patients, six had a response (one complete, five partial), with an ORR of 14.3% by RECIST v1.1. Median PFS was 2.7 months, median OS was 16.4 months, and DCR was 54.8%, with responders achieving a median DoR of 15.2 months. Therapy was generally well tolerated and resulted in an increase of immune activation markers, with higher levels of activation in peripheral blood associated with response and improved survival. The combination of Imprime and pembrolizumab was safe and demonstrated immune activation in tumor tissues and peripheral blood in patients with TNBC. Improved response rates were observed compared to historical studies of ICI monotherapy in similar patient populations.Study number (ClinicalTrials.gov trial registration): NCT02981303.

01 Nov 2024·Translational Lung Cancer Research

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

Article

Author: Furqan, Muhammad ; Liu, Li ; Malhotra, Jyoti ; Feldman, Lawrence ; Hulbert, Alicia ; Shergill, Ardaman ; Mott, Sarah L ; Kennedy, Kathleen ; Pasquinelli, Mary M

Background:

Therapeutic strategies to engage anti-tumor innate immunity are still underdeveloped. Imprime PGG (imprime), a pathogen-associated molecular pattern (PAMP), through pattern recognition receptors, successfully illicit a broad-based innate immune response in preclinical models against various cancers. We aimed to study safety and efficacy of imprime in combination with pembrolizumab in advanced stage non-small cell lung cancer (NSCLC).

Methods:

We conducted an investigator-initiated, multi-institutional, single-arm, phase Ib/II trial in previously treated, advanced stage NSCLC patients. Primary endpoints were maximum-tolerated dose (MTD) of imprime for the phase Ib, and progression-free survival (PFS) for the phase II study (NCT03003468).

Results:

All 33 eligible patients were included in the safety analysis. No dose-limiting toxicity was observed and the imprime dose of 4 mg/kg was determined as the MTD. Thirty patients treated at the MTD (phase Ib, 6; phase II, 24) were included in the efficacy analysis. Median length of follow-up was 10.8 months. Confirmed objective response rate was 10% [95% confidence interval (CI): 2-27%], with one complete and two partial responses. Median PFS was 2.6 months (95% CI: 1.4-7.0), and 6- and 12-month PFS rates were 37% and 17%, respectively. Median overall survival (OS) was 11.1 months, and 6- and 12-month OS rates were 75% and 46%. Univariate analysis was performed to assess the impact of age, sex, race, disease-stage, programmed death-ligand 1 (PD-L1) expression levels, and prior immunotherapy on PFS and OS. Of these, prior immunotherapy negatively influenced OS [hazard ratio (HR): 2.95, 95% CI: 1.21-7.24]. Overall, the combination was safe and tolerable.

Conclusions:

The combination of imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage NSCLC patients who previously progressed on anti-programmed death 1 (PD-1)/PD-L1 immunotherapies. Further investigation is needed to understand the effects of therapeutic PAMPs to mount a strong innate immune response against cancer.

01 Mar 2020·Anticancer researchQ4 · MEDICINE

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Q4 · MEDICINE

Article

Author: Jha, Gautam ; Qiu, Xiaohong ; Gorden, Keith ; Hurley, Peter J ; Gargano, Michele ; Bose, Nandita ; Rathmann, Blaine ; Ottoson, Nadine ; Harrison, Ben ; Dudek, Arkadiusz Z

BACKGROUND:

BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 antitumoral activity. We hypothesized that infusion of immunoglobulin can reinstate responses to BTH1677 in individuals with low ABA levels.

PATIENTS AND METHODS:

We report two single-patient studies: one in a patient with metastatic colorectal cancer who received BTH1677, combined with tumor targeting antibody cetuximab; and a second in a patient with metastatic neuroendocrine tumor who received BTH1677 combined with immune checkpoint inhibitor pembrolizumab.

RESULTS:

The patients had low serum titers of ABA and low innate immune effector functionality induced by BTH1677. Addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoral activity, with long-term disease control.

CONCLUSION:

Infusion of immunoglobulin can restore activity of BTH1677 in individuals with low serum ABA level.

9

News (Medical) associated with Odetiglucan

23 Oct 2024

·www.biospace.com

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

Phase 1Fast TrackPhase 2

29 May 2024

·www.globenewswire.com

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

Clinical StudyPhase 2

02 May 2024

·www.globenewswire.com

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

Phase 2AACR

100 Deals associated with Odetiglucan

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
KRAS Wild-type Colorectal Cancer	Phase 3	United States	HiberCell, Inc.	01 Apr 2011
KRAS Wild-type Colorectal Cancer	Phase 3	France	HiberCell, Inc.	01 Apr 2011
KRAS Wild-type Colorectal Cancer	Phase 3	Germany	HiberCell, Inc.	01 Apr 2011
KRAS Wild-type Colorectal Cancer	Phase 3	Puerto Rico	HiberCell, Inc.	01 Apr 2011
Colorectal Liver Metastases	Phase 2	United States	Merck Sharp & Dohme LLC	01 Sep 2025
Metastatic Colorectal Carcinoma	Phase 2	United States	Merck Sharp & Dohme LLC	01 Sep 2025
Breast Cancer	Phase 2	-	HiberCell, Inc.	28 Apr 2022
Metastatic breast cancer	Phase 2	United States	HiberCell, Inc.	09 Nov 2021
Advanced Head and Neck Squamous Cell Carcinoma	Phase 2	United States	HiberCell, Inc.	08 Nov 2017
metastatic non-small cell lung cancer	Phase 2	United States	HiberCell, Inc.	11 Jul 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00545545 (CTgov)	Phase 1/2	Colorectal cancer recurrent \| Colorectal Cancer	32	PGG+Cetuximab+Irinotecan (Arm 1, Imprime PGG Injection 2 mg/kg+ Cetuximab + Irinotecan)	myhxibmdga = eeokpawlcy pvwlvsnnxo (gzgfwybwwt, xlnpwipcpk - squnbefmkc) View more	-	19 Mar 2025
				PGG+Cetuximab+Irinotecan (Arm 1, Imprime PGG Injection 4 mg/kg+ Cetuximab + Irinotecan)	myhxibmdga = nvjqycvvkb pvwlvsnnxo (gzgfwybwwt, idzxcdrbxl - nfhgbrzgyn) View more
NCT03003468 (BTCRC LUN 15-017, Pubmed \| Transl Lung Cancer Res)	Phase 1/2	Non-Small Cell Lung Cancer	33	Imprime PGG 4 mg/kg + Pembrolizumab	zczruyfvbj(pzuvxjbssb) = mppdeutuuk ckwcedzvhw (dpqrievwmz ) View more	Negative	01 Nov 2024
NCT03003468 (BTCRC-LUN15-017 \| BTCRC LUN 15-017, CTgov)	Phase 1/2	metastatic non-small cell lung cancer	35	Imprime PGG+pembrolizumab (Phase Ib)	bgyyaxecom = qzfjxbgwms wjsvxriiia (wgcpzjkrnj, hemmilbluh - pogizqxexg) View more	-	13 Aug 2024
				PGG (Imprime PGG 4 mg/kg)	kkdnrckric(pxajgcyoju) = eypzppwicy otdvmuiegz (xiukovbfjb, jebwhpjvqo - rucwlgocge) View more
NCT02981303 (Phase 2 \| IMPRIME 1, CTgov)	Phase 2	Liver metastases \| Neoplasm Metastasis \| Triple Negative Breast Cancer ... View more	64	Imprime PGG+Pembrolizumab (Melanoma)	zfncutvbsj(clftlioasg) = eeegkalrbe mvvfgprqfq (jvxghmpxkj, jgocxxxpie - tyxcpwveqj) View more	-	09 Jul 2024
				Imprime PGG+Pembrolizumab (Triple Negative Breast Cancer)	zfncutvbsj(clftlioasg) = ofpextknwx mvvfgprqfq (jvxghmpxkj, iznhjcjqrd - xxkohwcpvk) View more
NCT05159778 (ASCO2022)	Phase 2	Metastatic breast cancer	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	bgatnrhhjn(ewrkzqcekz) = mkxtmbynjr kinhtndomw (yrbywdzsqr ) View more	-	02 Jun 2022
Abstract OT1-18-05 (SABCS2022)	Phase 2	Metastatic breast cancer PD-L1-positive	47	Imprime PGG 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	hlszcrjxwt(atkdjasser) = hiwxjewskl nmrjdcbkxl (ioxtsthxiz ) View more	Positive	15 Feb 2022
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) Manual	Phase 1/2	Non-Small Cell Lung Cancer	35	Pembro+Imprime PGG (phase Ib)	gtbjktnadf(pyywvekclg) = konqixvlwi cysdwrroed (qpiiqbjdqq, 1.28 - 27.8) View more	Negative	08 Sep 2021
				Pembro+Imprime PGG (phase II)	gtbjktnadf(pyywvekclg) = imvohkwekf cysdwrroed (qpiiqbjdqq, 1.35 - 5.13) View more
NCT02086175 (CTgov)	Phase 2	Refractory Indolent Non-Hodgkin Lymphoma \| Recurrent Indolent Non-Hodgkin Lymphoma	25	Imprime PGG+Rituximab	zxmyxtphth = oozrciexgx tkrilffkpu (jgxjwoihuw, sxyteujjku - bbhdxlxgbz) View more	-	07 Jan 2021
NCT02981303 (IMPRIME 1, AACR2020)	Phase 2	Metastatic Triple-Negative Breast Carcinoma	44	Imprime PGG + Pembrolizumab	xqsfjyuzlv(pydurnffvz) = cqpzfrmzfx pugmgkajid (kvyivgitzk, 7.9 - 29.4) View more	Positive	15 Aug 2020
NCT01269385 (CTgov)	Phase 1/2	Chronic lymphocytic leukaemia refractory	22	PGG beta-glucan+Rituximab+Alemtuzumab (Phase I: Dose Level 0)	wmzuyosvya = flyavchfxu ciygesklri (ejlatjhimr, ttcnzmxqtz - joleoyuukn)	-	23 Jun 2020
				PGG beta-glucan+Rituximab+Alemtuzumab (Phase I: Dose Level 1)	wmzuyosvya = trtggtrgps ciygesklri (ejlatjhimr, ajpvqvumgn - oxgznzwxmt)